0001144204-18-022823.txt : 20180427 0001144204-18-022823.hdr.sgml : 20180427 20180427060721 ACCESSION NUMBER: 0001144204-18-022823 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180427 FILED AS OF DATE: 20180427 DATE AS OF CHANGE: 20180427 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PRANA BIOTECHNOLOGY LTD CENTRAL INDEX KEY: 0001131343 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-49843 FILM NUMBER: 18780865 BUSINESS ADDRESS: STREET 1: P.O. BOX 655 CITY: CARLTON, SOUTH VIC STATE: C3 ZIP: 3053 BUSINESS PHONE: 61-0-9824-5254 MAIL ADDRESS: STREET 1: P.O. BOX 655 CITY: CARLTON, SOUTH VIC STATE: C3 ZIP: 3053 6-K 1 tv492325_6k.htm 6-K

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR

15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of April 2018

 

Prana Biotechnology Limited

(Name of Registrant)

 

Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia.

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x                   Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ¨                      No x 

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _____

 

This Form 6-K is being incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-199783) and Form S-8 (File No. 333-153669). 

 

 

 

 

 

PRANA BIOTECHNOLOGY LIMITED

 

6-K Items

 

1.

Appendix 4C

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

  PRANA BIOTECHNOLOGY LIMITED
    (Registrant)
     
     
  By: /s/ Geoffrey Kempler   
    Geoffrey Kempler,
    Executive Chairman

  

April 27, 2018

 

 

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

 

+Rule 4.7B

 

Appendix 4C

 

Quarterly report for entities subject to Listing Rule 4.7B

 

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

 

Name of entity
Prana Biotechnology Ltd
ABN   Quarter ended (“current quarter”)
37 080 699 065   31st March 2018

 

Consolidated statement of cash flows Current quarter
$A’000

Year to date 

(9 months)
$A’000

1. Cash flows from operating activities - -
1.1 Receipts from customers
1.2 Payments for (788) (2,477)
  (a) research and development
  (b) product manufacturing and operating costs - -
  (c) advertising and marketing (15) (67)
  (d) leased assets - -
  (e) staff costs (889) (2,607)
  (f) administration and corporate costs (894) (1,768)
1.3 Dividends received (see note 3) - -
1.4 Interest received 120 146
1.5 Interest and other costs of finance paid - -
1.6 Income taxes paid - -
1.7 Government grants and tax incentives - 3,023
1.8 Other (provide details if material) - -
1.9 Net cash from / (used in) operating activities (2,466) (3,750)

 

+ See chapter 19 for defined terms

1 September 2016

Page 1

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

 

Consolidated statement of cash flows Current quarter
$A’000

Year to date

(9 months)
$A’000

2. Cash flows from investing activities (36) (39)
2.1 Payments to acquire:
  (a) property, plant and equipment
  (b) businesses (see item 10) - -
  (c) investments - -
  (d) intellectual property - -
  (e) other non-current assets - -
2.2 Proceeds from disposal of: - -
  (a) property, plant and equipment
  (b) businesses (see item 10) - -
  (c) investments - -
  (d) intellectual property - -
  (e) other non-current assets - -
2.3 Cash flows from loans to other entities - -
2.4 Dividends received (see note 3) - -
2.5 Other (provide details if material) - -
2.6 Net cash from / (used in) investing activities (36) (39)

 

Consolidated statement of cash flows Current quarter
$A’000

Year to date

(9 months)
$A’000

3. Cash flows from financing activities - -
3.1 Proceeds from issues of shares
3.2 Proceeds from issue of convertible notes - -
3.3 Proceeds from exercise of share options - -
3.4 Transaction costs related to issues of shares, convertible notes or options - -
3.5 Proceeds from borrowings - -
3.6 Repayment of borrowings - -
3.7 Transaction costs related to loans and borrowings - -
3.8 Dividends paid - -
3.9 Other (receipt of funds upon expiry of term deposit towards rental guarantee) - 44
3.10 Net cash from / (used in) financing activities - (44)

 

+ See chapter 19 for defined terms

1 September 2016

Page 2

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

 

Consolidated statement of cash flows Current quarter
$A’000

Year to date

(9 months)
$A’000

4. Net increase / (decrease) in cash and cash equivalents for the period 20,030 21,884
4.1 Cash and cash equivalents at beginning of quarter/year to date
4.2 Net cash from / (used in) operating activities (item 1.9 above) (2,466) (3,750)
4.3 Net cash from / (used in) investing activities (item 2.6 above) (36) (39)
4.4 Net cash from / (used in) financing activities (item 3.10 above) - 44
4.5 Effect of movement in exchange rates on cash held 97 (514)
4.6 Cash and cash equivalents at end of quarter 17,625 17,625

 

5. Reconciliation of cash and cash equivalents
at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts
Current quarter
$A’000
Previous quarter
$A’000
5.1 Bank balances 9,508 10,030
5.2 Call deposits 8,117 10,000
5.3 Bank overdrafts - -
5.4 Other (provide details) - -
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above) 17,625 20,030

 

6. Payments to directors of the entity and their associates Current quarter
$A'000
6.1 Aggregate amount of payments to these parties included in item 1.2 202
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3 -
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Salaries, director’s fees and consulting fees at normal commercial rates.

Excludes GST where applicable.

 

+ See chapter 19 for defined terms

1 September 2016

Page 3

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

 

7. Payments to related entities of the entity and their associates Current quarter
$A'000
7.1 Aggregate amount of payments to these parties included in item 1.2 -
  Aggregate amount of cash flow from loans to these parties included in item 2.3 -
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

 

-

 

 

 

8. Financing facilities available
Add notes as necessary for an understanding of the position
Total facility amount at quarter end
$A’000
Amount drawn at quarter end
$A’000
8.1 Loan facilities - -
8.2 Credit standby arrangements - -
8.3 Other (please specify) - -
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

 

-

 

 

 

9. Estimated cash outflows for next quarter $A’000
9.1 Research and development 3,010
9.2 Product manufacturing and operating costs -
9.3 advertising and marketing 15
9.4 Leased assets -
9.5 Staff costs 900
9.6 Administration and corporate costs 535
9.7 Other (provide details if material) -
9.8 Total estimated cash outflows 4,460

 

+ See chapter 19 for defined terms

1 September 2016

Page 4

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

 

10. Acquisitions and disposals of business entities
(items 2.1(b) and 2.2(b) above)
Acquisitions Disposals
10.1 Name of entity - -
10.2 Place of incorporation or registration - -
10.3 Consideration for acquisition or disposal - -
10.4 Total net assets - -
10.5 Nature of business - -

 

Compliance statement

 

1This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

 

2This statement gives a true and fair view of the matters disclosed.

 

Sign here:     Date: 27 April 2018
  Company Secretary    
Print name: Phillip Hains    

 

 

Notes

 

1.

The quarterly report provides a basis for informing the market how the entity’s activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.

 

2.

If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

 

3.

Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

  

+ See chapter 19 for defined terms

1 September 2016

Page 5

 

GRAPHIC 2 image_002.jpg GRAPHIC begin 644 image_002.jpg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